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Abstract
Background: Understanding the global impact of medulloblastoma on health related 
quality of life (HRQL) is critical to characterizing the broad impact of this disease 
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1 |  INTRODUCTION
Medulloblastoma accounts for 20%-25% of all pediatric brain 
tumors in high income countries, but has a global impact on 
children's overall health.1 Survival rates for medulloblas-
toma have increased significantly due to improved treatment 
methods, with five year survival rates that range from 70% to 
85%.2-5 However, there is a disparity in survival rates in low 
to middle income countries—ranging from 33% to 73%.6,7 
Social, cognitive, and neurological long-term late effects 
have the potential to compromise the ongoing quality of life 
of survivors worldwide.8-12 Despite this global impact—
there is a dearth of internationally collaborative studies ex-
amining long-term outcomes in this vulnerable population. 
International studies investigating medulloblastoma primar-
ily focus on improving treatment protocols, however, even 
such studies demonstrate challenges in recruiting sufficient 
patients across multiple sites.13 Such studies are critical for 
characterizing the impact of this disease on health related 
quality of life (HRQL) and to implement the benefits of new 
knowledge about medulloblastoma across the world.
Previous studies on HRQL of brain tumor survivors 
have been limited to heterogeneous cohorts with multiple 
diagnoses and patients within the same continent (eg North 
America, Europe).14,15 HRQL of medulloblastoma survivors 
has been examined using patients within a single country.8,16 
An Italian cohort of medulloblastoma survivors displayed 
lower HRQL compared to those diagnosed with astrocytoma 
or a nontumor group.16 In a multicenter South Korean cohort, 
age at diagnosis for pediatric medulloblastoma survivors did 
not predict HRQL.8 Considering the worldwide impact of 
medulloblastoma, it would be beneficial to investigate HRQL 
across an international sample.
International collaboration has played an important role in 
advancing our understanding of the molecular diversity of me-
dulloblastoma. In particular, data obtained from large interna-
tional cohort studies, consensus statements, and meta-analyses 
have led to the identification of four distinct molecular sub-
groups of medulloblastoma: sonic hedgehog (SHH), Group 4, 
Group 3, and wingless (WNT).17-20 Considering the long-term 
negative effects of treatment, individualizing treatment based 
on molecular subgroup requires a balance between survival and 
HRQL. Similarly, an international focus on HRQL of survivors 
of pediatric medulloblastoma is important to realize the clini-
cal impact of molecular subgroups. Since the total number of 
childhood medulloblastoma survivors is relatively small, inter-
national collaboration is crucial to obtain sufficiently large sam-
ple sizes to accurately assess the impact of medulloblastoma on 
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and realizing the benefits of modern treatments. We evaluated HRQL in an interna-
tional cohort of pediatric medulloblastoma patients.
Methods: Seventy-six patients were selected from 10 sites across North America, 
Europe, and Asia, who participated in the Medulloblastoma Advanced Genomics 
International Consortium (MAGIC). The Health Utilities Index (HUI) was adminis-
tered to patients and/or parents at each site. Responses were used to determine overall 
HRQL and attributes (ie specific subdomains). The impact of various demographic 
and medical variables on HRQL was considered—including molecular subgroup.
Results: The majority of patients reported having moderate or severe overall bur-
den of morbidity for both the HUI2 and HUI3 (HUI2 = 60%; HUI3 = 72.1%) when 
proxy-assessed. Self-care in the HUI2 was rated as higher (ie better outcome) for pa-
tients from Western versus Eastern sites, P = .02. Patients with nonmetastatic status 
had higher values (ie better outcomes) for the HUI3 hearing, HUI3 pain, and HUI2 
pain, all P < .05. Patients treated with a gross total resection also had better outcomes 
for the HUI3 hearing (P = .04). However, those who underwent a gross total resec-
tion reported having worse outcomes on the HUI3 vision (P = .02). No differences in 
HRQL were evident as a function of subgroup.
Conclusions: By examining an international sample of survivors, we characterized 
the worldwide impact of medulloblastoma. This is a critical first step in developing 
global standards for evaluating long-term outcomes.
K E Y W O R D S
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HRQL. When doing so, it is important to consider international 
differences and specific disease factors, particularly subgroup 
status, on functional outcome.
Here, we examined HRQL—for the first time in a 
multi-continental cohort of pediatric medulloblastoma sur-
vivors—including survivors from North America, Europe, 
and Asia. We used the Health Utilities Index (HUI) (© 
Health Utilities Inc)21,22 as it is a widely used and well-vali-
dated measure of HRQL22 that has been employed in studies 
of childhood brain tumor survivors.23-25 The HUI provides 
scores for functional attributes including cognition, pain, and 
emotion, which are then aggregated to provide a score for 
overall burden of morbidity, a measure of the impact that the 
disease (ie medulloblastoma) has on overall HRQL. Most 
importantly, the HUI has been translated and administered 
in different languages, including English, Japanese, Korean, 
Portuguese and Dutch.22
Since HRQL has never been characterized in an interna-
tional sample of pediatric medulloblastoma survivors, our 
goal was to understand how subgroup and medical and de-
mographic variables impact HRQL in this population. By un-
derstanding how these factors impact HRQL, ultimately, this 
information can be used to determine if therapies should be 
modified for specific subgroups to improve HRQL without 
dramatically changing their prognosis.
2 |  MATERIALS AND METHODS
Seventy-six children with pathologic confirmation of me-
dulloblastoma participated in the study (SHH, n  =  16; 
Group 4, n  =  34; Group 3, n  =  15; and WNT, n  =  7). 
Subgroup information was unavailable for four patients. 
The Medulloblastoma Advanced Genomics International 
Consortium (MAGIC) tumor bank holds over 2000 fro-
zen medulloblastomas from more than 90 high quality 
pediatric neuro-oncology centers from around the world. 
Of these centers, 34 were approached and contacted via 
email. Twenty-one replied expressing interest in participat-
ing. Of those, ten obtained local ethics approval and pro-
vided data (Canada (n = 31): Toronto and Calgary; USA 
(n = 15): St. Louis, San Francisco, Columbus, and Aurora; 
Japan (n = 12): Sendai; South Korea (n = 13): Chonnam 
and Seoul; Portugal (n = 2): Lisbon; and the Netherlands 
(n  =  3): Rotterdam). Data was not received from  the re-
maining sites despite obtaining ethics approval, because 
data was not  received within the time frame required for 
the study (n = 5) or the site was lost to follow-up contact 
(n = 6). Each participating site identified eligible patients 
based on the following inclusion criteria (a) diagnosed 
with a medulloblastoma between August 1995 and August 
2010 and (b) tissue sample is included in the MAGIC tis-
sue bank. All participating sites obtained research ethics 
approval from their respective institutional boards and con-
formed to the ethical standards according to the Declaration 
of Helsinki.
Parents/guardians were included only if their child quali-
fied. Patients were excluded if (a) they were diagnosed with a 
medulloblastoma prior to August 1995 or after August 2010, 
or (b) their tissue sample was not included in the MAGIC 
tissue bank. Eligible participants were approached about the 
study during one of their hospital visits. Informed consent 
(and assent, where applicable) was obtained at each site prior 
to patients (and/or parent(s)/legal guardian(s)) completing 
the HUI. The HUI was completed at a single time point by 
each participant.
Demographic and medical features of the entire sample, 
by region and subgroup are summarized in Table 1. Patients 
treated with craniospinal irradiation (CSI) received either 
standard- (ie, 30.6 to 39.4 Gy) or reduced-dose (ie, 18.0 to 
23.4 Gy) radiation to the entire brain and spine with a boost 
to the posterior fossa or the primary tumor bed.
2.1 | Health Utilities Index
HRQL was evaluated using the 15-item questionnaire ver-
sion of the HUI. Results from the HUI can be tabulated to 
derive scores for two complementary systems: HUI Mark 
2 (HUI2)26 and HUI Mark 3 (HUI3).27 Respondents were 
asked to respond to the questions based on the patient's 
“usual” health status. At each site, the HUI was self-admin-
istered and completed by proxy- (parent/guardian) (n = 36) 
and/or self-assessed (for patients 12 years of age or older and 
with capacity; n = 13). Whenever possible, both proxy- and 
self-assessed versions were completed (n  =  27). Relevant 
translations of the HUI were employed for each site, includ-
ing either English, Dutch, Japanese, Portuguese, or Korean. 
Responses from the HUI were used to provide attribute levels 
and utility scores.
2.2 | Scoring of the HUI
Responses to the HUI were used to determine attribute lev-
els and single-attribute utility scores for the HUI3, then the 
HUI2, as some of the HUI3 attribute levels and utility scores 
are required to obtain scores for the HUI2. The HUI attribute 
levels and HUI single-attribute utility scores are not intended 
to provide clinical significance at the individual level, nor are 
there normative data associated with these scores. Rather, the 
HUI attribute levels and single-attribute utility scores reflect 
functional classes of disability. The HUI3 has eight attrib-
utes: (a) vision, (b) hearing, (c) speech, (d) emotion, (e) pain, 
(f) ambulation, (g) dexterity, and (h) cognition. Six attributes 
are obtained for the HUI2: (a) sensation, (b) mobility, (c) 
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cognition, (d) self-care, (e) emotion, and (f) pain. Attributes 
found in both the HUI2 and HUI3 include emotion, cognition 
and pain. These vary based on the following: (a) emotion in 
the HUI2 is based on anxiety whereas in the HUI3 it is based 
on happiness/unhappiness; (b) cognition in the HUI2 is based 
on learning and remembering whereas in the HUI3 it is based 
on forgetfulness and daily problem solving; and (c) pain in 
the HUI2 is based on the need for analgesics whereas in the 
HUI3 it is based on impairment of activities.28
Attribute levels are determined from responses provided 
for each multiple-choice question or combination of ques-
tions according to an algorithm described previously29 and 
differ between the HUI2 and HUI3. Attribute levels represent 
a range of functional classes that categorize the level of dis-
ability using a noninterval scale. For the HUI2, attribute lev-
els ranged from 1 to 4 (or 5), whereas for the HUI3 attribute 
levels ranged from 1 to 5 (or 6) (see Table 2). Attribute levels 
of 1 indicate normal/no impairment with increasing values 
reflecting increased impairment. The validity and reliability 
of the HUI system has been demonstrated in multiple lan-
guages, populations and across disease states.27,30-39
Attribute levels are converted into single-attribute utility 
scores40 that have interval scale properties ranging from 1.00 
(no morbidity) to 0.00 (worst level of impairment). Single-
attribute utility scores can be combined to obtain a multi-at-
tribute utility function score (overall burden of morbidity) 
each for the HUI2 and HUI3. Multi-attribute utility function 
scores have interval scale properties and range from 1.00 (no 
morbidity, perfect health) to 0.00 (dead). In order to receive a 
score of 1.00 (perfect health), the patient must have received 
a score of 1.00 at every attribute level. These utility scoring 
functions are based on published preference functions.26,27,40 
T A B L E  1  (a) Medical and demographic variables for the entire sample, by region (Western [Europe and North America] vs Eastern [Asia] 
sites), and subgroup (SHH, Group 4, Group 3 and WNT). (b) Missing medical and demographic variables for the entire sample, by region (Western 
[Europe and North America] vs Eastern [Asia] sites), and subgroup
(a) Medical and  
demographic variable
Entire sample
n = 76
Western sample
n = 51
Eastern sample
n = 25
SHH
n = 16
Group 4
n = 34
Group 3
n = 15
WNT
n = 7
Age at diagnosis (years)
Mean (SD) 6.71 (3.56) 6.82 (3.41) 6.48 (3.9) 4.65 (3.60) 7.62 (3.18) 6.52 (4.05) 8.28 (2.45)
Range 0.33-17.0 0.33-14.95 1.0-17.0 0.33-14.33 3.04-14.95 2.0-17.0 5.81-12.0
Time since diagnosis (years)
Mean (SD) 6.58 (4.00) 6.31 (4.14) 7.13 (3.74) 8.13 (4.05) 6.41 (3.84) 6.76 (4.85) 4.87 (2.23)
Range 0.54-17.67 0.92-17.67 0.54-15.91 2.67-15.91 0.54-16.51 1.24-17.67 0.92-6.88
Sex (% male) 70.7 68.0 76.0 62.5 67.6 86.7 57.1
Metastatic status (% 
M+)
25.3 28.0 20.0 18.8 29.4 20.0 42.9
Gross total resection 
(%)
85.1 79.6 88.0 93.8 75.8 93.3 85.7
CSI (%)
Standard dose 31.5 40.8 12.5 25.0 30.3 35.7 42.9
Reduced dose 65.8 57.1 83.3 62.5 69.7 64.3 57.1
None 2.7 2.0 4.2 12.5 0.0 0.0 0.0
Chemotherapy (%) 98.7 98.0 100.0 93.8 100.0 100.0 100.0
(b) Missing medical 
and demographic 
variable Entire sample Western sample Eastern sample SHH Group 4 Group 3 WNT
Age at diagnosis 1 1 0 0 0 0 0
Time since diagnosis 2 2 0 0 1 0 0
Sex 1 1 0 0 0 0 0
Metastatic status 1 1 0 0 0 0 0
Resection 2 2 0 0 1 0 0
CSI 3 2 1 0 1 1 0
Chemotherapy 1 1 0 0 0 0 0
Subgroup 4 4 0 N/A N/A N/A N/A
Abbreviations: M+, metastatic; SD, standard deviation; SHH, sonic hedgehog; WNT, wingless.
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Multi-attribute utility function scores (ie overall burden of 
morbidity) were categorized such that a score of 1.00 indi-
cated perfect health, a score of 0.89-0.99 indicated mild bur-
den of morbidity, a score of 0.70-0.88 indicated moderate 
burden of morbidity and a score of <0.70 indicated severe 
burden of morbidity.
2.3 | Molecular subgroup
Medulloblastoma samples were assigned subgroups by 
RNA NanoString technology, using the NanoString nCoun-
ter Analysis System at the University Health Network 
Microarray Centre. The content and methods have been de-
scribed previously.41
2.4 | Statistical analyses
2.4.1 | International sample
First, multi-attribute utility function scores representing 
overall burden of morbidity of medulloblastoma were char-
acterized as either perfect health (score of 1.00), mild (score 
of 0.89-0.99), moderate (score of 0.70-0.88), or severe (score 
of <0.70) for both the HUI2 and HUI3. We then calculated 
percentages for each burden of morbidity category. These 
percentages are reported separately for the self- and proxy-
assessed versions of the HUI.
2.4.2 | Regional comparisons
Both self-assessed and proxy-assessed scores were compared 
between sites from (a) Europe and North America (Western) 
versus (b) Asia (Eastern). Comparisons of all single-attrib-
ute utility scores and multi-attribute utility function scores 
(overall burden of morbidity) were conducted using Kruskal-
Wallis rank sum testing to determine if any regional differ-
ences existed in our sample. Since the HUI data is ordinal 
and not continuous, the  Kruskal-Wallis rank sum test  was 
used. For this test, we calculated effect size using the epsi-
lon-squared—which indicates the degree to which one group 
has data with higher ranks than the other group. For epsilon-
squared, 0.01 to <0.08 indicates a small effect size, 0.08 to 
<0.26 is a medium effect size, and ≥0.26 is considered a 
large effect size.42
2.4.3 | Sample by subgroup
Distributions of all single-attribute utility scores and multi-
attribute utility function scores (overall burden of morbidity) 
for the HUI2 and HUI3 as a function of subgroup were 
evaluated using Kruskal-Wallis rank sum test. As with the 
Regional comparisons, effect sizes were calculated using 
epsilon-squared where small effect sizes ranged from 0.01 
to <0.08, medium effect sizes ranged from 0.08 to <0.26 and 
large effect sizes ranged from ≥0.26. Post hoc analyses of 
significant overall subgroup effects were performed using 
Dunn's Multiple Comparisons Test (False Discovery Rate 
P = .05) to determine specific subgroup differences.
2.4.4 | Sample by medical and 
demographic variables
The impact of relevant medical and demographic variables 
on single-attribute utility scores and multi-attribute utility 
function scores (overall burden of morbidity) was examined. 
Gender, metastatic status, extent of resection, treatment with 
CSI, and treatment with chemotherapy were compared using 
Kruskal-Wallis rank sum test. As with the Regional com-
parisons and Sample by subgroup, effect sizes were calcu-
lated using epsilon-squared where small effect sizes ranged 
from 0.01 to <0.08, medium effect sizes ranged from 0.08 to 
<0.26 and large effect sizes ranged from ≥0.26. Spearman 
Rank correlations were used to examine relations between 
single-attribute utility scores and multi-attribute utility func-
tion scores (overall burden of morbidity) with age at diagno-
sis and time since diagnosis.
The data that support the findings of this study are avail-
able on request from the corresponding author. The data are 
not publicly available due to privacy or ethical restrictions.
3 |  RESULTS
3.1 | International sample
Percent burden of morbidity assessed by self and proxy as 
determined by the HUI2 and HUI3 are displayed in Figure 
1A,B, respectively. For the proxy-assessed scores, the ma-
jority of patients were rated as having moderate or severe 
overall burden of morbidity for both the HUI2 and HUI3 
(HUI2  =  60%; HUI3  =  72.1%). For both the HUI2 and 
HUI3, the least frequent rating for proxy-assessed scores 
was “perfect health” (HUI2 = 15%; HUI3 = 13.1%). In con-
trast, fewer patients reported moderate or severe overall bur-
den of morbidity for the HUI2 (45.9%), but not the HUI3 
(62.1%) based on self-assessed scores, and more reported 
“perfect health” or mild burden of morbidity on the HUI2 
(54%) when self-assessed versus 40% when proxy assessed. 
Frequencies and percentages for each attribute level for both 
proxy- and self-assessed scores on the HUI2 and HUI3 are 
displayed in Table 2.
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To maximize our sample size for the further analysis of 
region, subgroup, and medical and demographic variables, 
proxy-assessed scores were combined with self-assessed 
scores when only the latter were available (n = 76). We note 
that there were no significant differences in any single-attri-
bute utility scores for the proxy- and self-assessed versions 
in participants where both versions were acquired (P > .05). 
Furthermore, the distribution of overall burden of morbidity 
and attribution levels were similar for this combined proxy/
self-assessed sample as compared to proxy alone.
3.2 | Regional comparisons
Means, standard deviations, effect sizes (epsilon-squared), 
and P-values of single-attribute utility scores and multi-at-
tribute utility function scores (overall burden of morbidity) 
for Western versus Eastern sites are displayed in Table 3. 
Analyses revealed a statistically significant difference in the 
proxy-assessed single-attribute utility score for self-care on 
the HUI2 with a distribution of higher rank indicating bet-
ter outcomes, observed for the Western versus Eastern sites 
(H(1) = 5.280, Ɛ2 = 0.085, P =  .02). No other statistically 
significant differences were found among the other single-
attribute utility scores as a function of region when assessed 
by either proxy or self. In regards to overall burden of mor-
bidity, no significant regional differences were found with 
either the HUI2 or HUI3.
3.3 | Sample by subgroup
Kruskal-Wallis rank sum test results for comparisons of sub-
groups with single-attribute utility scores and multi-attribute 
utility function scores (overall burden of morbidity) are pre-
sented in Table 4. No statistically significant results were 
found.
3.4 | Sample by medical and 
demographic variables
Kruskal-Wallis rank sum test results for comparisons of 
medical and demographic variables with single-attribute util-
ity scores and multi-attribute utility function scores (overall 
burden of morbidity) are presented in Table 4. Patients with 
nonmetastatic status presented with higher values (ie bet-
ter outcomes) for HUI3 hearing (H(1) = 4.594, Ɛ2 = 0.061, 
P =  .03), HUI3 pain (H(1) = 4.806, Ɛ2 = 0.064, P =  .03) 
and HUI2 pain (H(1) = 3.976, Ɛ2 = 0.053, P = .05) than pa-
tients with a positive metastatic status (Figure 2A). Further, 
patients treated with a gross total resection had the highest 
values (ie better outcomes) for HUI3 hearing (H(1) = 4.150, 
Ɛ2 = 0.055, P = .04) and lowest values (ie worse outcomes) for 
the HUI3 vision (H(1) = 5.230, Ɛ2 = 0.070, P = .02) (Figure 
2B). No other statistically significant results were found. 
Finally, we observed a relation between time since diagno-
sis and HUI3 vision (Spearman Rank correlation P = −.256) 
suggesting that as survivors continue to grow and develop, 
vision problems worsen. No other correlations were found 
between the single-attribute utility scores and multi-attribute 
utility function scores (overall burden of morbidity) and age 
at diagnosis or time since diagnosis (Spearman Rank correla-
tions P > .05).
4 |  DISCUSSION
Here we expand the sparse body of literature examining 
HRQL in large multi-site cohorts of pediatric medulloblas-
toma survivors.43 Although medulloblastoma is the most 
common malignant brain tumor among children worldwide 
F I G U R E  1  Percent overall burden of morbidity (ie a measure 
of the impact that medulloblastoma has on patients) reported using the 
(A) HUI2 and (B) HUI3 as assessed by self and proxy. Scores were 
categorized such that a score of 1.00 indicated perfect health, a score 
of 0.89-0.99 indicated mild burden of morbidity, a score of 0.70-0.88 
indicated moderate burden of morbidity and a score of <0.70 indicated 
severe burden of morbidity
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the overall incidence of this disease is low (0.49 per 100 000 
children per year44). Consequently, obtaining both tissue sam-
ples and outcome data in large cohorts of medulloblastoma 
patients is challenging. Most studies of HRQL are limited 
to geographically homogeneous cohorts45 or heterogeneous 
brain tumor diagnoses.14,15 We show, for the first time, that 
HRQL is compromised in an international multi-continental 
sample of pediatric medulloblastoma survivors, where the 
majority of patients reported moderate or severe overall 
burden of morbidity following treatment when assessed by 
proxy. However, when patients completed the HUI, they re-
ported less moderate to severe burden of morbidity on the 
HUI2, but not the HUI3. This finding suggests that pediat-
ric brain tumor survivors do not interpret their abilities as 
burdensome as their caregivers. Caregiver expectations may 
be greater and since they are responsible for supporting and 
caring for the patients, they may compensate for some of the 
deficits the children have without the children realizing them.
In regards to HRQL according to geographic location 
(ie, North American and European versus Asian sites), we 
only observed a difference in HUI2 self-care such that pa-
tients from Western sites reported better performance com-
pared to those from Eastern sites, but only when assessed 
by proxy. Studies examining social competence in pediatric 
brain tumor survivors in Canada revealed that only patients 
diagnosed with medulloblastoma were found to have lower 
self-report ratings of social competence.46 This finding was 
purported to be associated with impairments in cognition and 
independent living, which have previously been reported.47,48
Overall, HRQL does not appear to be influenced by geo-
graphic factors in our international cohort. Our findings 
reinforce the global impact of this disease and the need for 
better understanding of current treatments on HRQL in not 
only Western, but also Eastern sites. As a global health issue, 
emphasis on international collaboration is required to reduce 
the burden of morbidity of this disease.
When individual medical variables were used to analyze 
outcome measures, we observed that patients with metastatic 
disease expressed worse hearing and pain outcomes. Typical 
standard of care for children with a positive metastatic status 
T A B L E  3  HUI2 and HUI3 single-attribute utility scores and multi-attribute utility function scores (ie overall burden of morbidity) as a 
function of region when assessed by proxy and self
Site
Proxy Self
Western Eastern
ε2 P-value
Western Eastern
ε2 P-valueMean SD Mean SD Mean SD Mean SD
HUI2
Sensation 0.929 0.06 0.934 0.06 0.000 .88 0.939 0.06 0.946 0.06 0.007 .61
Mobility 0.972 0.06 0.969 0.07 0.000 .93 0.977 0.05 0.961 0.09 0.003 .75
Cognition 0.96 0.03 0.98 0.03 0.035 .14 0.964 0.04 0.973 0.03 0.006 .63
Self-care 0.98 0.05 0.97 0.05 0.085 .02* 0.999 0.01 0.973 0.06 0.061 .12
Emotion 0.96 0.05 0.97 0.05 0.017 .3 0.939 0.08 0.952 0.08 0.005 .66
Pain 0.98 0.51 0.99 0.01 0.004 .62 0.991 0.01 0.992 0.01 0.003 .72
Overall 0.81 0.15 0.83 0.17 0.002 .71 0.824 0.18 0.809 0.19 0.002 .81
HUI3
Vision 0.99 0.04 0.99 0.01 0.011 .42 0.99 0.01 0.989 0.02 0.016 .43
Hearing 0.965 0.07 0.994 0.03 0.049 .08 0.979 0.06 0.995 0.02 0.013 .48
Speech 0.97 0.04 0.97 0.05 0.010 .44 0.983 0.03 0.978 0.04 0.001 .86
Cognition 0.89 0.11 0.93 0.08 0.021 .25 0.901 0.13 0.931 0.08 0.005 .68
Ambulation 0.96 0.08 0.95 0.11 0.000 .91 0.973 0.07 0.944 0.12 0.015 .44
Dexterity 0.97 0.05 0.96 0.09 0.000 .93 0.977 0.06 0.978 0.08 0.016 .42
Emotion 0.98 0.04 0.97 0.06 0.000 .94 0.952 0.09 0.975 0.04 0.008 .58
Pain 0.98 0.04 0.99 0.03 0.0245 .22 0.968 0.06 0.977 0.05 0.002 .77
Overall 0.67 0.25 0.72 0.31 0.011 .41 0.73 0.32 0.715 0.27 0.006 .62
Note: Single-attribute utility scores have interval scale properties ranging from 1.00 (no morbidity) to 0.00 (worst level of impairment). For overall burden of morbidity 
(multi-attribute utility function scores) a score of 1.00 indicates perfect health, a score of 0.89-0.99 indicates mild burden of morbidity, a score of 0.70-0.88 indicates 
moderate burden of morbidity and a score of <0.70 indicated severe burden of morbidity. Epsilon-squared (ε2) effect sizes: small = 0.01 to <0.08, medium = 0.08 to 
<0.26, and large = ≥0.26.
Abbreviations: ε2, epsilon-squared; SD, standard deviation.
*Indicates a statistically significant difference (P ≤ .05). 
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involves treatment with higher doses of CSI than those with 
nonmetastatic disease and CSI is typically associated with 
poorer hearing outcomes.49-51 Extent of resection was also 
found to have an impact on some single-attribute utility scores. 
Children who underwent a gross total resection reported hav-
ing better scores for hearing. Perhaps the successful surgical 
removal of the tumor minimized the amount of damage to 
the brain caused by any remaining tumor and/or resulted in 
reduced subsequent treatment intensity required to treat the 
residual tumor, similar to what is required for the metastatic 
disease outcomes described above. However, children who 
received a gross total resection reported worse vision scores. 
Medulloblastoma tumors are located in the posterior fossa, 
which is near the occipital lobe which is important for vision. 
During a gross total resection, perhaps some healthy tissue is 
damaged resulting in visual deficits.
Finally, when we correlated all single-attribute utility 
scores and multi-attribute utility function scores (overall 
burden of morbidity) with age at diagnosis and time since 
diagnosis, we only found a negative correlation between 
time since diagnosis and vision—as time since diagnosis in-
creases, pediatric medulloblastoma survivors reported having 
worse vision. In comparison to other pediatric brain tumors, 
medulloblastoma is associated with having one of the worst 
prognosis for vision outcomes (poor or fair).52 Vision prob-
lems are one of the late effects reported in medulloblastoma 
survivors.14 The negative impact on vision in medulloblas-
toma survivors is not surprising as primary vision brain 
structures are located at the back of the brain, near the area 
receiving the most treatment.
By examining a large international sample of survivors, 
we can characterize the impact of medulloblastoma world-
wide. This is a critical first step in developing standards 
for evaluating long-term outcomes in survivors of pediatric 
medulloblastoma. Since prognosis varies by subgroup (ie 
WNT good prognosis, Group 3 poor prognosis), determining 
HRQL posttreatment is important for refining current treat-
ment protocols. This is especially important when we con-
sider outcome differences between high and low to middle 
income countries. High income countries report incidence 
rates of 20%-25%, whereas low to middle income countries 
report 6.1%-49.4%.1 Diagnostic and treatment protocols vary 
across the world due to—among other things—financial and 
logistic factors.7,53 Ultimately, these inconsistencies can re-
sult in a disparity of survival rates and HRQL.54 As such, it 
would be interesting to see if our results would differ if low 
to middle income countries were included. Future studies ex-
ploring HRQL in medulloblastoma survivors using interna-
tional samples could further analyze the impact of those who 
live in high vs. low to middle income countries. Initiatives 
are underway to improve outcomes globally—for example, 
the SIOP Pediatric Oncology in Developing Countries group 
(PODC-SIOP) has made recommendations for treating me-
dulloblastoma in low to middle income countries, some of 
which include surgical techniques, timing and planning of 
CSI, and surveillance of late effects to help improve HRQL.1 
While the focus on such initiatives is survival, as outcomes 
improve we think it is equally important to consider HRQL in 
all childhood survivors of medulloblastoma—no matter their 
country of origin.
Limitations of this study include the use of a single mea-
sure of HRQL. Other validated questionnaires that have 
been translated into other languages, such as the World 
Health Organization WHOQOL-100 or WHOQOL-BREF or 
Pediatric Quality of Life Inventory, should be used to help 
verify our findings. Despite using an international sample, 
our cohort included patients predominately treated in North 
America and had few WNT patients. This was not surpris-
ing as WNT is the rarest subgroup, further emphasizing the 
F I G U R E  2  Significant findings (P < .05) for single-attribute 
utility scores from the HUI2 and HUI3 across the entire sample in 
relation to (A) metastatic status and (B) resection. Single-attribute 
utility scores range from 1.00 (no morbidity) to 0.00 (worst level of 
impairment). Mean values and standard error of the mean (SEM) are 
shown. GTR, gross total resection; M0, nonmetastatic; M+, metastatic
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need for multi-site collaboration. Despite this limitation, 
we do note that ours is the only cohort we are aware of that 
includes patients from Europe, Asia, and North America. 
However, we do not know the representativeness of our 
sample, since we do not have specific numbers regarding 
those who chose to participate and those who refused, po-
tentially leading to selection bias. Future studies should fur-
ther characterize the sample population by including details 
regarding the presence of hydrocephalus, cerebellar mutism, 
hormone deficiency, etc. In addition, we note that although 
our study combined proxy- and self-assessed versions, efforts 
should be made to obtain consistent respondent types, either 
proxy-assessed, self-assessed or both, in future studies using 
the HUI. Given the exploratory nature of this study, we did 
not correct for multiple comparisons, therefore findings may 
reflect the result of Type I error. HRQL was only assessed 
at one time point. As late effects continue to develop into 
widespread deficits, it would be beneficial to assess HRQL 
over time. These results could be used to plan long-term fol-
low-up services and initiate potential preventative measures. 
Our sample did not include any survivors from low to middle 
income countries. Since evidence shows a disparity between 
high and low to middle income countries, it is important to 
include patients from these countries when assessing HRQL 
in survivors.
Despite the significant advances in our knowledge of 
medulloblastoma and the resulting advantages of improved 
therapy, enhanced HRQL has not been realized globally. 
Promoting international collaboration with the incorporation 
of a standardized measure of HRQL is vital for improving 
patient outcomes for every child.
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